
Formpipe - Renewed Go-To-Market to Accelerate Lasernet Growth

Redeye reduces its Base Case slightly despite cutting its 2024-2025 EBIT forecasts following a soft Q1 report. While the issues in Public Deliveries are most likely temporary, the relatively low Private ACV is a greater concern. However, we are encouraged to see management's new initiatives to accelerate Lاسernet's growth.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Formpipe - Renewed Go-To-Market to Accelerate Lاسernet Growth](#)